Combo Products Hearing Anticipates GMP/QSR Jurisdiction, Legislated Office
This article was originally published in The Gray Sheet
Executive SummaryDetermination of good manufacturing practices (GMPs) and quality systems regulation (QSR) authority for combination products are among postmarket issues to be addressed at an FDA public hearing in Rockville, Maryland Nov. 25
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.